Back to Search Start Over

Cytokine-associated tissue injury and lethality in mice: A comparative study

Authors :
M. R. Shalaby
Terje Espevik
Lucien A. Aarden
K Matsushima
Anders Waage
J. Lamvik
O. A. Haugen
J. Halgunset
H. Aarset
Diana Boraschi
H. Kvithyll
Source :
Clinical Immunology and Immunopathology. 61:69-82
Publication Year :
1991
Publisher :
Elsevier BV, 1991.

Abstract

A comparative study was performed to examine the lethal effects of several cytokines injected into mice sensitized with actinomycin D (Act-D). Consistent with published data, human tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) (0.2-5 micrograms) caused the death of the animals within 8-12 hr after injection. Human interleukin-6 (IL-6) and interleukin-8 (IL-8) (0.6-6 micrograms) known to be induced by TNF-alpha did not show any lethal effects, indicating that TNF-alpha-associated lethality is not mediated by IL-6 or IL-8. Human tumor necrosis factor-beta (TNF-beta) (also called lymphotoxin), which shares structural and functional properties with TNF-alpha, was as potent as TNF-alpha in its lethal effects. Murine interferon-gamma (IFN-gamma) (0.04-5 micrograms) was also tested and showed no lethal effects in this model. In addition, a synthetic peptide corresponding to amino acid residues 163-171 of IL-1 beta, and which has been shown to lack the inflammatory effects of IL-1 beta, also caused no lethality among Act-D sensitized mice. The pretreatment of mice with IL-6, IL-8, or IFN-gamma had no protective effects on TNF-alpha or IL-1 beta-induced lethality in contrast to the protection observed by a pretreatment with TNF-alpha/IL-1 beta themselves or with endotoxin. Histopathologic data showed that severe tissue injury in vital organs is associated with the rapid lethality among sensitized mice.

Details

ISSN :
00901229
Volume :
61
Database :
OpenAIRE
Journal :
Clinical Immunology and Immunopathology
Accession number :
edsair.doi.dedup.....ffd90dca71e7f12f938386b775e93b86
Full Text :
https://doi.org/10.1016/s0090-1229(06)80008-5